Exploratory analysis of osteoarthritis progression among medication users: data from the osteoarthritis initiative
Open accessAbstract
BACKGROUND: We conducted an exploratory analysis of osteoarthritis progression among medication users in the Osteoarthritis Initiative to identify interventions or pathways that may be associated with disease modification and therefore of interest for future clinical trials. METHODS: = 2938). Consistent medication users were defined for each medication classification as a participant reporting at all four annual visits that they were regularly using an oral prescription medication at the time of the visit. The exploratory analysis focused on medication classes with 40 or more users. The primary outcome measures were medial tibiofemoral joint space width change and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) knee pain score change (12-36-month visits). Within each knee, we explored eight comparisons between users and matched or unmatched nonusers (defined two ways). An effect size of each comparison was calculated. Medication classes had potential signals if (a) both knees had less progression among users compared with nonusers, or (b) there was less progression based on structure and symptoms in one knee. RESULTS: We screened 28 medication classes. Six medication classes had signals for fewer structural changes and better knee pain changes: alpha-adrenergic blockers, antilipemic (excluding statins and fibric acid), anticoagulants, selective serotonin reuptake inhibitors, antihistamines, and antineoplastic agents. Four medication classes had signals for structural changes alone: anti-estrogen (median effect size = 0.28; range = -0.41-0.64), angiotensin-converting enzyme inhibitors (median effect size = 0.13; range = -0.08-0.28), beta-adrenergic blockers (median effect size = 0.09; range = 0.01-0.30), and thyroid agents (median effect size = 0.04; range = -0.05-0.14). Thiazide diuretics had evidence for symptom modification (median effect size = -0.12; range = -0.24-0.04). CONCLUSIONS: Users of neurovascular, antilipemic, or hormonal interventions may have less disease progression compared with nonusers.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The prevalent user design used in that study may be associated with bias and may account for the non-detection of fibrate effect on pain.
“used a prevalent user design (i.e. included participants who used fibrates at baseline) [62] that may be associated with bias [63] and may account for the non-detection of fibrate effect on pain.”
From Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy (2019) · cites this paper as [62]
In an exploratory study through the OAI database, neither reduced radiographic progression nor reduction in worsening of pain in participants taking fibrates were detected.
“In another exploratory study carried out through the OAI database, neither reduced radiographic progression nor reduction in worsening of pain in participants taking fibrates were detected.”
From Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy (2019) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., Wang, H., Abumrad, N., Eaton, J. W., & Tracey, K. J. (2000) · Nature · doi:10.1038/35013070 · Cited by 4,211 · see citing works
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 972 · see citing works
MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529 · see citing works
Brain gray matter decrease in chronic pain is the consequence and not the cause of pain
Rodriguez-Raecke, R., Niemeier, A., Ihle, K., Ruether, W., & May, A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3687-09.2009 · Cited by 527 · see citing works
Drug data coding and analysis in epidemiologic studies
Pahor, M., Chrischilles, E. A., Guralnik, J. M., Brown, S. L., Wallace, R. B., & Carbonin, P. (1994) · European Journal of Epidemiology · doi:10.1007/bf01719664 · Cited by 490 · see citing works
Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis
Suri, S., Gill, S. E., de Camin, S. M., McWilliams, D. F., Wilson, D., & Walsh, D. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.063354 · Cited by 423 · see citing works
Inflammation and angiogenesis in osteoarthritis
Haywood, L., McWilliams, D. F., Pearson, C. I., Gill, S. E., Ganesan, A., Wilson, D., & Walsh, D. A. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11094 · Cited by 396 · see citing works
Brain Morphological Signatures for Chronic Pain
Baliki, M. N., Schnitzer, T. J., Bauer, W. R., & Apkarian, A. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026010 · Cited by 369 · see citing works
Cytokines and the immunomodulatory function of the vagus nerve
Johnston, G. R., & Webster, N. R. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep037 · Cited by 201 · see citing works
Griffin, T. M., Fermor, B., Huebner, J. L., Kraus, V. B., Rodriguiz, R. M., Wetsel, W. C., Cao, L., Setton, L. A., & Guilak, F. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3068 · Cited by 200 · see citing works
Mease, P. J., HANNA, S., Frakes, E. P., & Altman, R. D. (2011) · The Journal of Rheumatology · doi:10.3899/jrheum.100759 · Cited by 175 · see citing works
Hussain, S. M., Wang, Y., Cicuttini, F., Simpson, J. A., Giles, G. G., Graves, S. E., & Wluka, A. E. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.07.013 · Cited by 141 · see citing works
Clockaerts, S., van Osch, G. J. V. M., Bastiaansen-Jenniskens, Y. M., Verhaar, J. A. N., Glabbeek, F. V., van Meurs, J. B. J., Kerkhof, H. J. M., Albert Hofman, D., Stricker, B. H. C., & Bierma‐Zeinstra, S. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200092 · Cited by 140 · see citing works
Duryea, J., Neumann, G., Niu, J., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20148 · Cited by 126 · see citing works
Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study
Hoeven, T. A., Kavousi, M., Clockaerts, S., Kerkhof, H. J. M., van Meurs, J. B. J., Franco, O. H., Albert Hofman, D., Bindels, P., Witteman, J. C. M., & Bierma‐Zeinstra, S. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201178 · Cited by 124 · see citing works
Li, H., George, D. M., Jaarsma, R. L., & Mao, X. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.48 · Cited by 114 · see citing works
Location specific radiographic joint space width for osteoarthritis progression
Neumann, G., Hunter, D. J., Nevitt, M. C., Chibnik, L. B., Kwoh, K. C., Chen, H. A., Harris, T. B., Satterfield, S., & Duryea, J. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2008.11.001 · Cited by 110 · see citing works
Self-citationKanis, J. А., Johansson, H., Odén, A., et al. (2010) · Bone · doi:10.1016/j.bone.2010.06.009 · Cited by 98 · see citing works
Bergman, A. G., Will�n, H., Lindstrand, A., & Pettersson, H. (1994) · Skeletal Radiology · doi:10.1007/bf00204605 · Cited by 97 · see citing works
Osteochondral angiogenesis and increased protease inhibitor expression in OA
Franses, R. E., McWilliams, D. F., Mapp, P. I., & Walsh, D. A. (2009) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2009.11.015 · Cited by 86 · see citing works
Saadat, E., Jobke, B., Chu, B., et al. (2008) · European Radiology · doi:10.1007/s00330-008-0989-7 · Cited by 75 · see citing works
New radiographic-based surrogate outcome measures for osteoarthritis of the knee
Duryea, J., Zaïm, S., & Genant, H. K. (2003) · Osteoarthritis and Cartilage · doi:10.1053/joca.2002.0866 · Cited by 74 · see citing works
Gierman, L. M., van der Ham, F., Koudijs, A., Wielinga, P. Y., Kleemann, R., Kooistra, T., Stoop, R., Kloppenburg, M., van Osch, G. J. V. M., Stojanovic-Susulic, V., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33443 · Cited by 72 · see citing works
Elliott, M. B., Barr, A. E., Kietrys, D. M., Alshatti, T. A., Amin, M., & Barbe, M. F. (2008) · Brain Research · doi:10.1016/j.brainres.2008.04.029 · Cited by 45 · see citing works
Bergman, A. G., Rogero, G. W., Hellman, B. H., & Lones, M. A. (1994) · Skeletal Radiology · doi:10.1007/bf02412368 · Cited by 35 · see citing works
Abourazzak, F., Talbi, S., Lazrak, F., et al. (2015) · Current Rheumatology Reviews · doi:10.2174/1573397111666150522093337 · Cited by 35 · see citing works
Treatment of allergic rhinitis can improve blood pressure control
Magen, E., Yosefy, C., Viskoper, R. J., & Mishal, J. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002088 · Cited by 18 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy
Nogueira-Recalde, U., Lorenzo-Gómez, I., Blanco, F. J., Loza, M. I., Grassi, D., Shirinsky, V., Shirinsky, I., Lotz, M., Robbins, P. D., Domínguez, E., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.049 · Cited by 155 · see citing works
Role of the autonomic nervous system in osteoarthritis
Courties, A., Sellam, J., & Berenbaum, F. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.04.001 · Cited by 66 · see citing works
- Authors
- Driban, J. B., Lo, G. H., Eaton, C. B., Lapane, K. L., Nevitt, M., Harvey, W. F., McCulloch, C. E., & McAlindon, T. E.
- Affiliations
- Tufts Medical Center (US)
- Michael E. DeBakey VA Medical Center (US)
- Brown University (US)
- University of Massachusetts Chan Medical School (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- Therapeutic Advances in Musculoskeletal Disease
- Publisher
- SAGE Publications
- Published
- 2016-09-16
- Volume
- 8
- Issue
- 6
- Pages
- 207-219
- ISSN
- 1759-720X (ISSN-L)
- 1759-7218
- PMC
- PMC5322858
- OpenAlex
- W2516700189
- Cited by
- 36
- References
- 27
- Citations by year
- 2026: 3 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 6 · 2019: 6 · 2018: 4 · 2017: 2
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Therapeutic Advances in Musculoskeletal Disease (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Health and Human Services (N01-AR-2-2258, N01-AR-2-2261, N01-AR-2-2262, N01-AR-2-2259, N01-AR-2-2260)
- U.S. Department of Veterans Affairs
- Pfizer (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262)
- GlaxoSmithKline (N01‐AR‐2‐2261, N01-AR-2-2258, N01-AR-2-2260, N01-AR-2-2259, N01-AR-2-2262)
- Health Services Research and Development (HFP90‐020)
- Novartis Pharmaceuticals Corporation (N01-AR-2-2261, N01-AR-2-2262, N01-AR-2-2260, N01-AR-2-2258, N01-AR-2-2259)
- National Institutes of Health (HFP90-020, N01 AR‐2‐2260, N01-AR-2-2258, N01‐AR‐2‐2259, N01-AR-2-2261, N01-AR-2-2262)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR062127)
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Health Sciences › Medicine › Pharmacology › Musculoskeletal pain and rehabilitation
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- osteoarthritis progression, knee osteoarthritis, medication use, disease modification, joint space narrowing, anticoagulants, selective serotonin reuptake inhibitors, antihistamines, antiestrogens, ACE inhibitors, beta-blockers, thiazide diuretics, alpha-blockers, anticancer agents, hormonal interventions, neurovascular interventions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
